High Voltage Leak Detection (HVLD) is a deterministic container closure integrity testing (CCIT) method used for suitable liquid-filled pharmaceutical packaging. It applies a controlled high-voltage, low-current electrical measurement to identify changes associated with leakage through the container.

One question pharmaceutical manufacturers frequently raise is whether exposure to high voltage can affect the drug product inside the package.

HVLD is generally considered a nondestructive testing method, but its impact on product quality should be evaluated for the specific formulation, container, and test conditions. The application of high voltage alone does not establish that a pharmaceutical product will be damaged, nor does a nondestructive classification guarantee that every formulation is unaffected.

This article examines the HVLD measurement principle, potential product quality concerns, packaging compatibility, and the studies needed to establish method suitability.

1. How Does HVLD Work with Liquid-Filled Pharmaceutical Packaging?

High Voltage Leak Detection uses electrical conductivity and capacitance measurements to evaluate package integrity.

During testing, electrodes apply a controlled high-voltage, low-current electrical signal to the sealed package. The system monitors the resulting electrical response.

For a suitable nonconductive container holding a conductive liquid, an intact package and a leaking package may produce different electrical signals.

When a defect establishes an electrical pathway involving the liquid product, the measured current or electrical response can change. The system evaluates this change against defined acceptance criteria.

HVLD is commonly investigated for:

• Liquid-filled pharmaceutical vials.

• Glass ampoules.

• Prefilled syringes.

• Pharmaceutical cartridges.

• Suitable infusion containers.

• Other compatible liquid-filled pharmaceutical packaging.

The method does not require opening the package or directly contacting the drug product with an external probe.

However, detection capability depends on the electrical characteristics of the product-package system, defect location, electrode arrangement, and established testing parameters.

2. Can HVLD Damage Liquid Pharmaceutical Products?

HVLD is generally classified as nondestructive because the testing procedure can evaluate a sealed package without intentionally altering or opening it.

Nevertheless, the effect of the electrical exposure on the formulation should be distinguished from the ability of the system to detect packaging defects.

Electrical Exposure and Product Quality

HVLD uses high voltage with limited current, typically applied for a controlled period.

The actual electrical exposure depends on the instrument design, test parameters, electrode configuration, and characteristics of the product-package system.

It should not be assumed that the drug product experiences the full nominal voltage indicated by the instrument.

Similarly, nominal operating voltage alone does not provide sufficient information to assess formulation compatibility.

Potential Effects on Pharmaceutical Formulations

For a particular product, the assessment may need to consider whether testing influences:

• Chemical stability and degradation.

• Protein structure or aggregation.

• Biological activity or potency.

• Appearance, color, or turbidity.

• Particulate formation.

• Other relevant critical quality attributes.

These are potential evaluation endpoints, not established consequences of routine HVLD exposure.

The relevant endpoints depend on the formulation and its known quality risks.

What Does Published Research Show?

Published research has examined HVLD exposure in an insulin aspart solution packaged in form-fill-seal plastic laminate bags.

Under the investigated testing and storage conditions, the study did not identify adverse effects on the evaluated drug product stability.

This provides evidence that HVLD can be compatible with a sensitive pharmaceutical formulation under defined conditions.

However, the findings should not be generalized to every biologic, drug formulation, container material, or HVLD system without additional assessment.

3. What Factors Determine HVLD Product Compatibility?

The suitability of HVLD depends on the complete product-package system.

Evaluation Factor	Relevance to Product Quality and Testing
Drug Formulation	Determines which physicochemical and biological quality attributes may require assessment
Electrical Conductivity	Influences the electrical measurement and leak detection response
Applied Voltage	Forms part of the defined electrical exposure conditions
Current and Exposure Duration	Contribute to the characterization of electrical exposure
Container Material	Affects electrical insulation, measurement behavior, and testing compatibility
Fill Volume and Headspace	Influence liquid coverage of potential leakage pathways
Electrode Arrangement	Determines which regions of the package are examined
Defect Location	Influences whether a leak produces a detectable electrical response

These factors should be investigated during method development rather than evaluated individually without reference to the complete system.

4. Which Liquid Products Are Suitable for HVLD Testing?

HVLD suitability depends partly on the electrical properties of the formulation.

Aqueous Injectable Solutions

Many aqueous injectable products contain dissolved substances that provide electrical conductivity.

Such formulations may be suitable for HVLD when the container material and testing configuration support a measurable distinction between intact and defective packages.

Conductivity should be evaluated using the actual product rather than assumed from the fact that the formulation is water-based.

Biological Pharmaceutical Products

Biologics, including protein-based formulations, may require additional product compatibility assessment.

The relevant concerns include potential effects on protein stability, aggregation, potency, and other formulation-specific quality attributes.

Available scientific studies demonstrate that HVLD can be compatible with certain protein formulations, but suitability should be confirmed for the actual drug product and exposure conditions.

Ophthalmic Solutions and Infusion Products

Liquid ophthalmic products and infusion solutions may also be evaluated using HVLD when their electrical properties and packaging systems are appropriate.

Relevant factors include liquid conductivity, container geometry, material, fill volume, and the locations where leakage may occur.

Low-Conductivity Formulations

Products with relatively low electrical conductivity may produce different detection responses from conductive aqueous formulations.

The achievable detection capability depends on the particular measurement technology and instrument configuration.

Low conductivity should therefore trigger a feasibility assessment rather than an automatic assumption that HVLD cannot be used.

5. How Does Container Design Affect HVLD Testing?

Container compatibility is important both for reliable leak detection and for evaluating the complete testing procedure.

Packaging Type	Relevant Characteristics	Method Development Considerations
Glass Vials	Glass wall, liquid fill, stopper and aluminum cap	Liquid coverage, electrode position, closure geometry, and electrical response
Glass Ampoules	Fused glass seal and container body	Fill level, neck geometry, accessible inspection regions, and defects
Prefilled Syringes	Barrel, plunger stopper, and tip closure	Liquid position, headspace, syringe orientation, and closure interfaces
Pharmaceutical Cartridges	Glass body and movable sealing components	Liquid coverage, stopper position, and inspection arrangement
BFS Containers	Polymer walls and formed sealing regions	Material electrical properties, geometry, and liquid coverage
IV Bags	Flexible polymer packaging, seals, and ports	Package shape, electrode accessibility, and inspection feasibility

Liquid Coverage and Defect Location

HVLD relies on a measurable electrical response associated with a leakage pathway.

For a partially filled vial or syringe, a defect located in a gas-filled region may not behave in the same way as one in contact with the liquid.

Sample orientation or movement may be used in a validated test procedure to establish appropriate liquid coverage.

However, not every closure region will necessarily be accessible or detectable under the same conditions.

Packaging Material

Glass and suitable polymer materials can provide electrical insulation between the external electrodes and the liquid contents.

Differences in wall thickness, material properties, and package geometry can influence the resulting measurement.

The method must therefore be evaluated for the actual packaging configuration.

6. Product Damage Risk vs. Leak Detection Risk

Product compatibility and test reliability are separate validation questions.

Risk Category	Main Question	Evaluation Approach
Product Quality	Does HVLD exposure affect the formulation's critical quality attributes?	Compare relevant product quality data before and after defined HVLD exposure
Container Compatibility	Is the packaging suitable for the electrical testing procedure?	Examine material, geometry, electrical response, and package condition
Leak Detection Capability	Can the method detect relevant leakage pathways?	Evaluate appropriately characterized positive controls
False Rejection	Can intact packages produce signals outside the acceptance limits?	Test representative intact samples and establish decision criteria
Missed Defects	Could relevant leaks fail to produce detectable signals?	Evaluate defect locations, fill conditions, and method detection capability
Method Robustness	Do normal operating variations affect test results?	Investigate relevant parameter variations and repeatability

An HVLD system may demonstrate suitable product compatibility but still require further optimization to reliably detect relevant leakage defects.

Likewise, demonstrating leak detection capability does not automatically establish that the method has no impact on the drug formulation.

Both questions should be addressed according to the intended use.

7. How to Evaluate the Effect of HVLD on Product Stability

For formulations where electrical exposure raises a scientifically relevant concern, a product compatibility study can provide supporting evidence.

Step 1: Define the Product Quality Attributes

Identify the critical quality attributes that could be affected by the testing procedure.

For a protein formulation, these may include potency, aggregation, appearance, and relevant chemical degradation parameters.

For a small-molecule injectable, the assessment may focus on assay, related substances, appearance, and other formulation-specific attributes.

Step 2: Establish Representative Testing Conditions

Record the instrument configuration and relevant electrical testing parameters, including voltage, current characteristics where available, electrode arrangement, and exposure duration.

The study should reflect the intended operating procedure.

Step 3: Compare Tested and Control Samples

Assess representative HVLD-exposed samples against suitable control samples using scientifically justified analytical methods.

Where applicable, the evaluation may include repeated exposure or conditions selected to investigate potential cumulative effects.

Step 4: Evaluate Stability When Relevant

For products with potential delayed quality effects, stability assessment may be appropriate.

The duration and test parameters should be justified according to the product characteristics and study objective.

Step 5: Document the Findings

Record the testing conditions, analytical methods, results, and conclusions supporting the suitability of HVLD exposure for the intended application.

The extent of the study should be based on product-specific risk assessment rather than a single universal protocol.

8. How Are HVLD Detection Capability and Method Validation Established?

In addition to product compatibility, pharmaceutical manufacturers must demonstrate that the HVLD method can reliably identify defects relevant to the container closure integrity requirements.

Positive Control Selection

Appropriately characterized CCIT positive controls can support evaluation of the instrument's response to known defective packages.

Positive controls should represent relevant defect sizes, locations, and configurations.

A laser-drilled hole in a container wall does not necessarily reproduce leakage at a stopper or another closure interface.

Detection Capability

Method development should establish whether relevant defects can be detected using the proposed electrode arrangement, product fill conditions, and test parameters.

The nominal diameter of a positive control defect should not automatically be equated with a specific electrical response or universal leakage rate.

Repeatability and Robustness

Testing should evaluate the consistency of results and the influence of relevant operating variations.

These may include electrode position, container orientation, fill level, and other established method parameters.

Acceptance Criteria

The method should use scientifically justified pass/fail criteria supported by representative intact and defective packages.

Although HVLD produces an electrical measurement, the method is commonly implemented as a package integrity pass/fail test rather than a direct measurement of absolute leakage rate.

9. USP <1207> and HVLD Product Safety Considerations

USP <1207> addresses pharmaceutical package integrity evaluation and includes high-voltage leak detection among deterministic leak testing technologies.

HVLD is generally regarded as nondestructive when the testing procedure does not adversely affect the container or its contents.

For pharmaceutical applications, manufacturers should evaluate:

• Product-package compatibility.

• The effects of HVLD exposure on relevant product quality attributes.

• Defect detection capability under actual test conditions.

• Positive control suitability.

• Repeatability and robustness.

• Scientifically justified acceptance criteria.

• Applicable method validation and documentation requirements.

The classification of HVLD as deterministic does not independently demonstrate product compatibility or regulatory compliance.

A validated testing procedure should address the intended package integrity requirement and any relevant product quality concerns.

10. HVLD Testing Solutions from Zholion

Founded in 2005, Zholion provides container closure integrity testing equipment and technical services for pharmaceutical packaging.

Zholion's MC-E24 High Voltage Leak Detector uses high-voltage microcurrent technology for suitable liquid-filled pharmaceutical packaging, including vials, ampoules, prefilled syringes, cartridges, and other compatible container configurations.

Zholion also provides:

• CCIT method development and validation services.

• Positive control samples for method performance studies.

• Technical evaluation of pharmaceutical product-package systems.

• Third-party package integrity testing services.

• Regulatory documentation and audit support.

For pharmaceutical manufacturers evaluating HVLD, Zholion can assist in assessing product conductivity, packaging structure, testing parameters, and relevant CCIT validation requirements.

Manufacturers should provide their drug formulation characteristics, container specifications, fill conditions, and testing objectives when requesting a technical evaluation.

Frequently Asked Questions

Does HVLD damage liquid pharmaceutical products?

HVLD is generally considered nondestructive under suitable testing conditions. However, the effect of electrical exposure on relevant product quality attributes should be evaluated for the specific formulation and testing procedure.

Can HVLD change the chemical composition of an injectable drug?

A change should not be assumed solely because high voltage is applied. Product-specific compatibility studies may be required to determine whether the testing procedure affects chemical stability or other quality attributes.

Is HVLD suitable for protein-based formulations?

HVLD can be evaluated for protein-based formulations. Published research has demonstrated compatibility with a particular insulin formulation under defined conditions, but the findings should not be generalized without product-specific assessment.

Does higher voltage always increase leak detection capability?

No. Detection performance depends on the complete electrical measurement arrangement, product conductivity, package material, defect characteristics, and testing parameters. Higher voltage alone does not guarantee improved performance.

Can HVLD detect defects above the liquid level?

Detection depends on whether the defect produces a measurable electrical response under the established testing conditions. Headspace, container orientation, and liquid coverage may influence detection.

Is HVLD suitable for every liquid-filled container?

No. Suitability depends on product conductivity, container material, geometry, defect location, and the capabilities of the selected testing system.

Does using HVLD automatically satisfy USP <1207>?

No. The method must be evaluated and validated for the intended product-package system. Technology classification alone does not establish compliance.

Conclusion

HVLD is an established deterministic method for evaluating container closure integrity in suitable liquid-filled pharmaceutical packaging.

Although it is generally considered nondestructive, the effect of electrical exposure on product quality should be assessed according to the formulation, container, instrument configuration, and testing conditions.

Product compatibility and leak detection capability are two distinct requirements. Both should be supported by relevant development studies and method validation.

Zholion provides high-voltage leak detection equipment and CCIT technical services to help pharmaceutical manufacturers evaluate the suitability of HVLD for their actual product-package systems.